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Abstract
Background: Bone metastases are a common and dismal consequence of lung cancer that is a leading cause of
death. The role of IL-7 in promoting bone metastases has been previously investigated in NSCLC, but many
aspects remain to be disclosed. To further study IL-7 function in bone metastasis, we developed a human-in-mice
model of bone aggression by NSCLC and analyzed human bone metastasis biopsies.
Methods: We used NOD/SCID mice implanted with human bone. After bone engraftment, two groups of mice
were injected subcutaneously with A549, a human NSCLC cell line, either close or at the contralateral flank to the
human bone implant, while a third control group did not receive cancer cells. Tumor and bone vitality and IL-7
expression were assessed in implanted bone, affected or not by A549. Serum IL-7 levels were evaluated by ELISA.
IL-7 immunohistochemistry was performed on 10 human bone NSCLC metastasis biopsies for comparison.
Results: At 12 weeks after bone implant, we observed osteogenic activity and neovascularization, confirming bone
vitality. Tumor aggressive cells implanted close to human bone invaded the bone tissue. The bone-aggressive
cancer cells were positive for IL-7 staining both in the mice model and in human biopsies. Higher IL-7 serum levels
were found in mice injected with A549 cells close to the bone implant compared to mice injected with A549 cells
in the flank opposite to the bone implant.
Conclusions: We demonstrated that bone-invading cells express and produce IL-7, which is known to promote
osteoclast activation and osteolytic lesions. Tumor-bone interaction increases IL-7 production, with an increase in
IL-7 serum levels. The presented mice model of bone invasion by contiguous tumor is suitable to study bone-
tumor cell interaction. IL-7 plays a role in the first steps of metastatic process.
Background
Lung cancer is a major cause of cancer-related deaths
[1]. More than 90% of deaths due to lung cancer can be
attributed to metastases [2], which are frequently
observed at the time of diagnosis. After liver and brain,
bone represents the most common target organ [3].
Osteolytic bone metastases worsen prognosis, causing
morbidity [4] and also having substantial financial impli-
cations for the health-care providers [5]. The low suc-
cess rate in treating lung cancer depends on a still
incomplete understanding of the metastatic process and
on the lack of sensitive markers to predict and monitor
tumor progression [6].
The role of IL-7 in diseases characterized by bone loss
[7] and in bone metastases [8-10] has been deeply inves-
tigated by us and others. Particularly, we identified IL-7
as a potential marker of Non-Small Cell Lung Cancer
(NSCLC) progression to bone. The role of IL-7 produc-
tion by tumor cell is still elusive, but it may be pivotal
in metastasis pathogenesis. In physiological conditions
IL-7 is usually subject to strict regulation, while produc-
tion is rarely affected. Disfunction of this fine regulation
can only be found in severely impaired osteoimmunolo-
gic situations [11-13].
In the last years, important advances provided new
animal models of different human cancer metastasis to
human tissues [14-16]. Some models gave important
contributions to the disclosure of the osteotropic
mechanisms. They involved the implant of both human
tumor cells and human bone as a metastatic target in
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non-obese diabetic severe combined immunodeficiency
(NOD/SCID) mice, allowing the study of the cell-cell
interactions within all human tissues at the target site.
In this work, a human-in-mice model was adopted; a
human bone implant was susceptible to metastatic
spread, as previously described by Kuperwasser et al. to
study spread through circulation from orthotopic site
[14]. We rather focused on bone-tumor interaction,
studying direct invasion by a tumor mass growing close
to the engrafted bone. The tumors derived from subcu-
taneous injection of a human NSCLC cell line, A549.
We studied the IL-7 production by bone invading cells
and we tested the IL-7 expression in bioptic tissues
from human secondary bone lesions, due to NSCLC.
Methods
Cell culture
A NSCLC cell line with osteotropic characteristics, the
A549, was purchased from the American Type Culture
Center (ATCC). Cells were cultured in F-12K Medium,
Modified 2 mM L-glutamine e 1500 mg/L sodium bicar-
bonate (ATCC), 10% fetal bovine serum (FBS) (Sigma-
Aldrich, St Louis, MO) with antibiotics, according to
manifacturer’s conditions. Sub-confluent cells were
washed by PBS and harvested by trypsinization.
Animals and surgery
A colony of 18 NOD/SCID 7-week-old female mice
(Charles River Laboratories, Calco, Milan) were housed
under aseptic sterile conditions. Experimental animals
were treated in compliance with the actual national and
international guidelines (the Italian legislative decree
116/92 and the European Community Directive 86/609
CEE) and in accordance to the authorization provided
by Italian Ministry of Health (as of D.M. 44/1994-A and
subsequent integrations).
Mice were given autoclaved food and water ad libi-
tum. A 0.5 cm3 cube-shaped human bone implant,
obtained from the discarded head bone of an adult
patient submitted to total joint replacement (after the
patient’s informed consent), was immediately trans-
planted sub-cutaneously in the left flank in all animals.
Surgery was performed in sterile conditions and in gen-
eral anaesthesia. Animals received antibiotics (Enrofloxa-
cin 2.5% 1 ml/1 L) in the drinking water up to 2 weeks
following all surgical procedures.
The bone implants were allowed to engraft in the mice
for 4 weeks; then mice were divided in three groups of six
animals each, as follows: a) mice subjected only to bone
implant (control); b) mice injected with A549 cells close to
the bone implant (group #1); c) mice injected with A549
cells in the opposite flank to the bone implant (group #2).
In particular, 1 × 106of cells were resuspended in PBS and
Matrigel 1:3 (BD Biosciences, Bedford, MA) and injected in
volume of 40 μL sub-cutaneously, using a 25-gauge needle.
Eight weeks after cancer cell injection, mice were
euthanized; primary tumors, bone implants, lungs and
spleens were excised and processed for immunohisto-
chemistry and other analyses.
Histology and immunohistochemistry
Immunohistochemistry was performed on tissues fixed
in 10% neutral buffered formalin and bone tissues were
decalcified with EDTA treatment until soft. Tissues
were embedded in paraffin and 4 micron sections were
deparaffinized, rehydrated through graded alcohols, and
subjected to antigen retrieval for immunohistochemistry.
Sections were stained for H&E to study the morphology
and incubated with mouse monoclonal antibodies
against human-specific CD34, clone QBEnd/10 (Neo-
Markers, Fremont, CA) and human IL-7 (R&D Systems,
Abingdon, UK). IL-7 staining was performed also on 10
human biopsies derived from bone metastasis by
NSCLC. Research on human specimen was carried out
in compliance with the Helsinki Declaration. IL-7
expression in mice and human tissues was quantifed
based on IL-7 staining intensity.
Fluorescence-activated cell sorting analysis and ELISA
FACS analysis was performed on whole NOD/SCID
mice spleens. Spleen tissue was dissociated with forceps
and cells were re-suspended in D-MEM with 10% FBS.
Cells were passed through a 40 μm cell strainer and re-
suspended in red blood cell lysis buffer. Two million
cells were incubated with antibodies specific for human
IgG-phycoerythrin (PE). Spleen cells were analyzed on a
FACSCalibur system to identify the human IgG-PE posi-
tive cell population after gating out PI positive cells.
Samples were analyzed in a FACsCalibur instrument
and elaborated by CellQuest software.
To dose serum IL-7 levels we performed an ELISA
assay, according to the manifacturer’s instructions (R&D
Systems, Abingdon, UK). The kit sensitivity was 0.27-8.7
pg/mL.
Results
Analysis of viability and activity of implanted
human bone
A human bone was implanted in NOD/SCID mice,
according to the previously described method [14].
Twelve weeks post-implantation the human bone
implants, mouse spleens, lungs and blood were collected
from the xenografted hosts. Survivorship and percentage
of bone and lung metastatic invasion are listed in table 1.
H&E staining of bone implants showed mineralized bone
and stromal cells (Fig. 1A). In detail, osteocytes as well as
fat cells, areas of solid mineralized bone, osteoblast lining
cells throughout these areas, bone forming activity
(Fig. 1B-C) and bone marrow (Fig. 1D) were observed
in situ. The vascularization of the grafts was examined
and neo-angiogenesis surrounding the implanted bone
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was detected. (To determine the species origin of
endothelial cells in blood vessels supplying the bone
implants, sections were examined by immunohistochem-
istry using human-specific CD34 antibodies). The pre-
sence of human derived blood vessels was confirmed by
CD34 staining of human blood vessels (Fig 2), while
mouse vessels were not stained. The human vasculature
remained viable within bone for periods of 12 weeks.
To further demonstrate that human bone marrow pre-
cursors were functional, we analyzed by FACS the pre-
sence of human IgG in the host mouse spleens, showing
their presence in mice with bone implant, whereas no
IgG were found in the control mouse spleens, 12 weeks
after human bone implantation (data not shown).
NSCLC cells invade the implanted human bone
The A549 is a NSCLC cell line with osteotropic ability.
A rapid tumor growth was obtained at the implantation
site in all animals. When tumor cells were injected close
to the bone chip, the tumor invaded the normal
implanted human bone, disrupting it. Metastases were
not observed in the group where tumor cells were
injected in the contralateral flank. H&E staining of bone
implant with tumors showed large areas of invading
tumor cells surrounding live human bone, with presence
of fat cells, blood vessels, and osteoblasts (Fig 3).
NSCLC bone invading cells express IL-7
IL-7 expression by A549 cells was evaluated, showing a
high IL-7 expression by tumor cells of epithelial origin.
IL-7 expression in tumor masses was observed in both
groups. The analysis of bone invaded by tumor cells and
bone contralateral to the tumor mass, showed a differ-
ent intensity of IL-7 expression. In detail, bone invaded
by tumor cells showed a stronger level of IL-7 expres-
sion than contralateral bone, where IL-7 was expressed
only by stromal cells (Fig. 4A, B). In human biopsies,
IL-7 was highly expressed by bone invading cells
(Fig. 4C). The intensity of IL-7 expression is reported in
Table 1.
Serum IL-7 is high in mice with bone invasion
Since we previously demonstrated that serum IL-7 levels
are higher in NSCLC patients with bone metastases
than in patients without bone lesions, we tested the IL-7
production in the two groups of mice, by dosing serum
IL-7.
Significantly higher levels of IL-7 were found in mice
injected with A549 cells close to the bone implant com-
pared to mice injected with A549 cells in the opposite
flank (0.57 ± 0.01 and 0.25 ± 0.03 pg/ml, respectively;
p < 0.001), while no significant difference was found
between opposite flank and control group without
Figure 1 Histologic analysis of human bone implants. Representative H&E-stained section of human bone fragment implanted
subcutaneously in NOD/SCID mice 12 weeks post implantation (A). Magnifications show newly synthesized bone, osteocytes, fat cells, areas of
solid mineralized bone and osteoblast lining cells, as labelled by the arrows (B and C). Human bone marrow remains localized in the marrow
spaces, as indicated in D. Magnification: A 100×, B 250×, C 250×, D100×.
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Figure 2 Immunohistochemical staining of human bone implants. Immunohistochemistry was performed on serial sections using human-
specific CD34 antibodies to delineate human blood vessels, which are shown within and around bone xenografts (arrows). Magnification 250×.
Figure 3 Histologic analysis of A549 metastases in human implanted bone. H & E-stained sections show large areas of invading tumor cells
surrounding live human bone, with presence of fat cells, blood vessels, and osteoblasts, as labeled by the arrows. Magnification 100×.
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tumor cells. The IL-7 serum value in the control group
was 0.21 ± 0.03 pg/ml (Fig. 5).
Discussion
One barrier to the disclosure of cancer osteotropism
mechanism is the lack of animal models that reflect the
complex biology of the metastatic process in humans
[17]. Some models are limited to intra-cardiac or
intravenous (tail vein) injection, where cancer cells are
directly seeded into circulation, bypassing the early steps
of the metastatic process [18-21]. The result is a process
that may be quite different from what happens in
humans, where tumor cells undergo a phenotype selec-
tion before and during metastatic spread to the circula-
tion. Moreover, human tumor cells interact with mouse
tissue at the target site possibly introducing a further
bias.
Recently, new animal models provided important
advances for investigations of human bone metastasis
[14-16]. These models involve implant of both human
tumor cells and a xenograft of human tissue as meta-
static target in NOD/SCID mice, allowing cell-cell inter-
actions within all human tissues at the target site and a
selection of the metastatic phenotype.
In the models where metastatic target is human bone
tissue, the Kuperwasser method [14] worked only in a
selected cell line over thirteen tested. No molecular
explanation or hypotesis was provided and the model
was never used by other authors. Another model, pro-
posed by Yang and colleagues [16], required the implant
of bone tissue at the site of primary tumor seeding in
order to obtain metastasis at a target bone site, a very
peculiar condition, quite different from conventional
human metastatic process.
The model proposed in this study is based on human
bone invasion by a contiguous human tumor mass; it
doesn’t replicate the comprehensive metastatic process
(evasion from primary tumor, vessel invasion and survi-
val in the blood circulation), rather focuses on cancer
cell bone invasion capability. It allowed us to bypass
technical difficulties related to obtaining NSCLC metas-
tases through blood circulation. The opposite flank
injection group was useful for serum IL-7 level compari-
sons, in order to discriminate production related to
bone invasion from production by tumor mass alone.
To the author’s knowledge, this is the first human-in-
mice NSCLC bone invasion model described in litera-
ture. The general validity of this model is supported by
results on bone vitality and implanted tumor growth.
The specific validity for studies on tumor-bone interac-
tions in metastasis is highlighted by the histologic and
cytokine production analyses. Bone invasion appeared to
have the same histological characteristics of human
metastasis, such as bone resorption, neo-apposition and
tumor nested within the bone tissue. The immunohisto-
chemical staining of bone invaded by NSCLC cells,
showed a strong expression of IL-7; the same result was
obtained by the staining performed on human tissues
from bone biopsies of patients affected by NSCLC bone
metastasis. Staining for IL-7 of the bone implanted con-
tralateral to the tumor showed stromal cells positive for
IL-7 expression, as expected and according to the
Figure 4 IL-7 expression by NSCLC bone invading cells in
mouse and human biopsies. A strong IL-7 level expression is
shown by tumor cells in invaded bone (A). In contralateral bone,
IL-7 level expression is detectable on stromal cells and it is lower
than in bone invaded by tumor cells (B). In human biopsies, IL-7 is
highly expressed by bone invading cells (C). Magnification 100×.
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literature [22,23]. In the past, the Authors showed that
increase in IL-7 serum levels relates to NSCLC bone
metastasis but couldn’t demonstrate the capability of
bone metastatic cells to directly produce IL-7 [10]. Here
we show that NSCLC bone invading cells expressed and
produced detectable quantities of IL-7 both in human
metastasis and in our model. The IL-7 expression by
tumor mass (in mice with contralateral bone) and by
bone stromal cells did not lead to high serum IL-7
levels. In fact, the highest IL-7 serum levels were
detected in the experimental group where tumor cells
invaded the human bone target. Thus, interactions
between tumor cells and bone increased the IL-7 serum
levels, as demonstrated in patients [24].
We speculate that the mechanism underlying interac-
tion between cancer cells and bone closely resembles
the metastatic mechanism in humans, therefore this
model might be valuable and considered for further
testing.
Conclusions
We demonstrated that bone invading cells directly
express and produce IL-7, which is known to promote
osteoclast activation and osteolytic lesions. Both tumor
cells and bone stroma can produce IL7 but cross-talk
between the two increases production, as shown both in
humans and in the described mice model. Our mice
model of bone invasion by contiguous tumor mass
showed similar histology and IL-7 patterns compared to
human pathology. We believe it to be suitable for stu-
dies on bone-tumor cell interaction, being both realistic
and technically feasible compared to other models.
We believe that new studies on the first steps of meta-
static process and on the role of IL-7 are due, consider-
ing together the fine mechanism through which IL-7 is
regulated, its role in pathologies characterized by bone
loss and the sudden intense increase in IL-7 production
when bone is invaded by tumor cells.
Acknowledgements
We wish to thank the Compagnia di San Paolo and the Regione Piemonte
(Ricerca Sanitaria Finalizzata 2008) for their financial support.
Author details
1CeRMS (Center for Experimental Research and Medical Studies) University of
Turin and A.O.U. San Giovanni Battista, Turin, Italy. 2Department of
Orthopaedics, A.O.U. San Giovanni Battista, Turin, Italy. 3Department of
Experimental Medicine (DIMES), University of Genoa, Italy. 4Department of
Pathology, A.O.U. San Giovanni Battista, Turin, Italy. 5ABC Advanced
Biotechnology Center, Genoa, Italy. 6Department of Animal Pathology,
University of Turin, Grugliasco, Italy. 7University of Genoa - Department of
Motor Sciences, Italy. 8Department of Medical Oncology, A.O.U. San Giovanni
Battista, Turin, Italy.
Authors’ contributions
IR: conception and design of the study, analysis and interpretation of data,
carried out part of laboratory assessment and the draft of the manuscript.
DC: conception and design of the study, analysis and interpretation of data,
carried out part of the experimental surgery and the draft of the manuscript.
LG: carried out and analysis of immunohistochemical staining. LD: carried
out laboratory assessment. PG: was responsible for animal care and surgical
procedures. EM: carried out part of the experimental surgery. QR: critical
revisal of the manuscript. LM: interpretation of data. PB: critical revisal of the
manuscript. AM: critical revisal of the manuscript. RF: interpretation of data,
critical revisal of the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 July 2009
Accepted: 12 January 2010 Published: 12 January 2010
Table 1 mouse groups and human biopsies summary data
Survivorship Bone metastatic invasion Intensity of IL-7 staining Metastasis in lung tissue
Control 5/6 (83%) 0 +
(stromal cells)
0
Group #1 5/6 (83%) 4/5 +++
(tumor cells and stromal
cells)
micro-
metastasis 1/5
Group #2 6/6 (100%) 0 +
(stromal cells)
0
10 Human biopsies - 10/10 +++ -
Control indicates mice subjected only to bone implant; group #1 indicates mice injected with A549 cells close to the bone implant; group #2 indicates mice
injected with A549 cells in the opposite flank to the bone implant.
Figure 5 Serum IL-7 levels in mice. In mice injected with A549
cells close to the bone implant IL-7 is significantly higher than in
mice injected with A549 cells in the opposite flank, p < 0.001. There
was not significant difference between opposite flank and the
control group without tumor cells.
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